Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LGVN Longeveron Inc

Market Closed 10-09 16:00:00 EDT

2.48

+0.11

+4.64%

盘后2.48

+0.000.00%

19:04 EDT

High2.60	Low2.34	Vol58.46K
Open2.40	D1 Closing2.37	Amplitude10.97%
Mkt Cap7.84M	Tradable Cap6.76M	Total Shares3.16M
T/O141.56K	T/O Rate2.14%	Tradable Shares2.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LGVN","market":"US","secType":"STK","nameCN":"Longeveron Inc","latestPrice":2.48,"timestamp":1791576000000,"preClose":2.37,"halted":0,"volume":58460,"hourTrading":{"tag":"盘后","latestPrice":2.48,"preClose":2.48,"latestTime":"19:04 EDT","volume":21,"amount":49.48,"timestamp":1791587076272,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.04641350210970459,"floatShares":2725530,"shares":3159795,"eps":-10,"marketStatus":"Market Closed","change":0.11,"latestTime":"10-09 16:00:00 EDT","open":2.4,"high":2.6,"low":2.34,"amount":141556.429502,"amplitude":0.109705,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-10,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"listingDate":1613106000000,"exchange":"NASDAQ","adjPreClose":2.37,"preHourTrading":{"tag":"盘前","latestPrice":2.33,"preClose":2.37,"latestTime":"06:50 EDT","volume":840,"amount":1964.43996,"timestamp":1791543050186,"change":-0.04,"changeRate":-0.016878,"amplitude":0.016878},"postHourTrading":{"tag":"盘后","latestPrice":2.48,"preClose":2.48,"latestTime":"19:04 EDT","volume":21,"amount":49.48,"timestamp":1791587076272,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0286349763040095},"requestUrl":"/m/hq/s/LGVN/wiki","defaultTab":"wiki","newsList":[{"id":"2672823177","title":"Longeveron Says Phase 2b Trial Shows Laromestrocel Improves Physical Condition in Age-Related Frailty Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2672823177","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672823177?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:07","pubTimestamp":1790798834,"startTime":"0","endTime":"0","summary":"Longeveron says Phase 2b trial shows laromestrocel improves physical condition in age-related frailty patientsLongeveron highlighted Phase 2b results showing its laromestrocel cell therapy improved ph","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL8r8GCz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","SG9999014005.SGD","SG9999014039.USD","BK4112","IE00BKPKM429.USD","SG9999014021.USD","LU2210150020.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","BCDF","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","BK4139","LU0314104364.USD","BK4585","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","NDAQ","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4588","LU2210149790.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672825977","title":"Longeveron to Participate in Three Longevity/Aging Investment Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2672825977","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672825977?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:05","pubTimestamp":1790798700,"startTime":"0","endTime":"0","summary":"New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce Neuroinflammation in the Brain, A Core Driver of AD Pathogenesis, Publishe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3372378/0/en/longeveron-to-participate-in-three-longevity-aging-investment-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4575","BK4132","BK4139","MSC","BK4150","LGVN","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669435025","title":"Longeveron Says ELPIS II Phase 2b Trial of Laromestrocel in HLHS Misses Primary Endpoint at 12 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2669435025","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669435025?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:02","pubTimestamp":1790193739,"startTime":"0","endTime":"0","summary":"Longeveron says ELPIS II Phase 2b trial of laromestrocel in HLHS misses primary endpoint at 12 monthsLongeveron reported topline results from its ELPIS II Phase 2b trial of laromestrocel in infants wi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL73yH2Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669715971","title":"Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Longeveron (LGVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669715971","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669715971?lang=en_us&edition=fundamental","pubTime":"2026-09-21 16:50","pubTimestamp":1789980613,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Bausch + Lomb Corporation (BLCO) and Longeveron (LGVN) with neutral ratings, indicating that the expe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bausch-lomb-corporation-blco-and-longeveron-lgvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bausch-lomb-corporation-blco-and-longeveron-lgvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0029874061.USD","LU0128526141.USD","BK4581","BK4137","LGVN","BK4585","XLV","BK4198","BLCO","BK4139","HCSG","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668699177","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2668699177","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668699177?lang=en_us&edition=fundamental","pubTime":"2026-09-18 02:36","pubTimestamp":1789670197,"startTime":"0","endTime":"0","summary":"Longeveron's  phase 2b trial of stem cell therapy laromestrocel in 40 infants with hypoplastic left heart syndrome failed to meet its primary endpoint of a change in right ventricular ejection fraction at Month 12, the company said late Wednesday.Shares slumped 58% as intraday trading volume climbed to over 1.2 million from a daily average of about 47,000.Viant Technology  announced late Wednesday an underwritten public offering of 8.5 million Class A shares by a selling stockholder.Shares sank 17% as intraday trading volume soared to over 1.0 million from the stock's daily average of roughly 256,000.Fluence Energy  cut fiscal 2026 revenue guidance, citing ongoing supply chain issues impacting its US production. Baird downgraded Fluence to underperform from neutral and adjusted its price target to $3 from $10.Fluence shares fell 15% as intraday trading volume climbed to over 27.4 million from a daily average of about 7.6 million.Price: 2.83, Change: -3.85, Percent Change: -57.63","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FLNC","BK4585","LU2357125470.USD","DSP","BK4588","BK4023","LU0823414478.USD","LGVN","LU0823414551.USD","BK4096","LU2249611893.SGD","LU2506951792.HKD","BK4139","LU2294711713.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668999169","title":"Longeveron Stock (LGVN) Plummets 56% on a Failed Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2668999169","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668999169?lang=en_us&edition=fundamental","pubTime":"2026-09-18 00:44","pubTimestamp":1789663452,"startTime":"0","endTime":"0","summary":"Longeveron stock took a 56.14% beating on Thursday after the company posted a failed clinical trial.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/longeveron-stock-lgvn-plummets-56-on-a-failed-clinical-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/longeveron-stock-lgvn-plummets-56-on-a-failed-clinical-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","LGVN","NVIB","HYLG","MEDX","BK4139","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668939505","title":"Stocks to Watch: Generac, Vicor, Longeveron, Viant","url":"https://stock-news.laohu8.com/highlight/detail?id=2668939505","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668939505?lang=en_us&edition=fundamental","pubTime":"2026-09-17 06:34","pubTimestamp":1789598040,"startTime":"0","endTime":"0","summary":"Generac signed a $2.4 billion deal to sell data-center generators to Amazon.com. Shares jumped 35%, to $237, in after-hours trading Wednesday.Vicor granted a license to a new original equipment manufacturer. The stock gained 11%, to $204, after the bell.Longeveron said a recent trial to treat a heart condition in children failed to meet its primary endpoint. Shares sank 60%, to $2.69.Viant Technology said one of its stockholders would offer 8.5 million shares in an underwritten public offering. The stock shed 10%, to $11.10.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2249611893.SGD","DSP","BK4096","CNRG","LU0053671581.USD","GNRC","LU2394011477.USD","LU2298321311.HKD","BK4023","BK4139","BK4588","VICR","LU0823414478.USD","LU0266013472.USD","LU2041044095.USD","LU2360108059.USD","LGVN","BK4585","LU1878469433.USD","LU2092937221.SGD","LU2089985449.USD","LU0274383776.USD","LU2931357623.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668936701","title":"Longeveron Explores Strategic Options After Therapy Fails Mid-Stage Trial for Infant Heart Condition","url":"https://stock-news.laohu8.com/highlight/detail?id=2668936701","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668936701?lang=en_us&edition=fundamental","pubTime":"2026-09-17 06:15","pubTimestamp":1789596944,"startTime":"0","endTime":"0","summary":"Longeveron explores strategic options after therapy fails mid-stage trial for infant heart conditionSept 17 (Reuters)-LongeveronLGVN.Oon Wednesday said it would explore strategic options after its exp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nL4N4581LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668467936","title":"Longeveron Exploring Options to Maximize Shareholder Value After Heart Disease Drug Misses Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2668467936","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668467936?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:55","pubTimestamp":1789595700,"startTime":"0","endTime":"0","summary":"Longeveron initiated a process of exploring options to maximize shareholder value after a stem cell therapy to treat a heart condition in children failed to meet its primary endpoint in a Phase 2b tri","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668936133","title":"Longeveron Says ELPIS II Trial of Laromestrocel in Hypoplastic Left Heart Syndrome Misses Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2668936133","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668936133?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:45","pubTimestamp":1789595138,"startTime":"0","endTime":"0","summary":"Longeveron says ELPIS II trial of laromestrocel in hypoplastic left heart syndrome misses primary endpointLongeveron reported topline results from its ELPIS II Phase 2b trial of laromestrocel in infan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL470YQQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4585","SG9999014039.USD","IE00BQXX3D17.EUR","LGVN","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","LU2095319765.USD","NDAQ","IE00BQXX3C00.GBP","BCDF","LU2210150020.SGD","BK4112","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668928936","title":"Longeveron to resume trading at 5:55 pm ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2668928936","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668928936?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:40","pubTimestamp":1789594820,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) is scheduled to resume quoting at 5:50 pm ET and to resume trading at 5:55 pm ET, according to Nasdaq. Shares were halted, pendin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-to-resume-trading-at-555-pm-et-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-to-resume-trading-at-555-pm-et-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LGVN","LCLG","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668936994","title":"Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2668936994","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668936994?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:35","pubTimestamp":1789594520,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) announced topline results from ELPIS II, its Phase 2b clinical trial evaluating its investigational stem cell therapy laromestroc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeverons-laromestrocel-did-not-meet-primary-endpoint-in-phase-2b-hlhs-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeverons-laromestrocel-did-not-meet-primary-endpoint-in-phase-2b-hlhs-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGVN","IBBQ","FBT","HYLG","SYNB","IDNA","GNOM","IBB","TBXU","MEDX","BK4585","LFSC","BK4139","GDOC","CNCR","NVIB","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668593694","title":"Longeveron exploring all options for maximizing shareholder value","url":"https://stock-news.laohu8.com/highlight/detail?id=2668593694","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668593694?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:35","pubTimestamp":1789594516,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) has initiated a process of optimizing cost containment and will explore all options with the goal of maximizing shareholder value...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-exploring-all-options-for-maximizing-shareholder-value-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-exploring-all-options-for-maximizing-shareholder-value-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668936548","title":"Longeveron Announces Topline Results from Elpis Ii Phase 2B Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (Hlhs)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668936548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668936548?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:27","pubTimestamp":1789594036,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nTUA546RXN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668936545","title":"Longeveron - no Deaths in Laromestrocel-Treated Patients over 12 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2668936545","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668936545?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:27","pubTimestamp":1789594036,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nTUA546RXN:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668936512","title":"Longeveron - Company Initiates Process to Optimize Cost Containment and Maximize Shareholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2668936512","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668936512?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:27","pubTimestamp":1789594036,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nTUA546RXN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668527936","title":"Longeveron: Intends to Pursue Funding Sources & Other Potential Revenue Opportunities to Advance Laromestrocel in Longevity & Aging-Related Frailty","url":"https://stock-news.laohu8.com/highlight/detail?id=2668527936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668527936?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:27","pubTimestamp":1789594036,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nTUA546RXN:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668365179","title":"Longeveron Inc: Initiated a Process to Review All Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2668365179","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668365179?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:27","pubTimestamp":1789594036,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nTUA546RXN:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668193651","title":"Longeveron - Elpis Ii Trial Did not Meet Primary Endpoint of Rvef Improvement at Month 12","url":"https://stock-news.laohu8.com/highlight/detail?id=2668193651","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668193651?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:27","pubTimestamp":1789594036,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nTUA546RXN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668350839","title":"Longeveron Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2668350839","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668350839?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:55","pubTimestamp":1789592109,"startTime":"0","endTime":"0","summary":"16:55 EDT Longeveron (LGVN) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-inc-trading-halted-news-pending-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-inc-trading-halted-news-pending-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.longeveron.com","stockEarnings":[{"period":"1week","weight":-0.0388},{"period":"1month","weight":-0.6231},{"period":"3month","weight":-0.6326},{"period":"6month","weight":-0.7862},{"period":"1year","weight":-0.7197},{"period":"ytd","weight":-0.5099}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.0313},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1417}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.146765},{"month":2,"riseRate":0,"avgChangeRate":-0.052774},{"month":3,"riseRate":0.5,"avgChangeRate":0.19338},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.138428},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.132971},{"month":6,"riseRate":0.666667,"avgChangeRate":0.086991},{"month":7,"riseRate":0.5,"avgChangeRate":0.154004},{"month":8,"riseRate":0,"avgChangeRate":-0.277244},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.188833},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.015261},{"month":11,"riseRate":0.4,"avgChangeRate":1.291039},{"month":12,"riseRate":0,"avgChangeRate":-0.282059}],"exchange":"NASDAQ","name":"Longeveron Inc","nameEN":"Longeveron Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Longeveron Inc,LGVN,Longeveron Inc股票,Longeveron Inc股票老虎,Longeveron Inc股票老虎国际,Longeveron Inc行情,Longeveron Inc股票行情,Longeveron Inc股价,Longeveron Inc股市,Longeveron Inc股票价格,Longeveron Inc股票交易,Longeveron Inc股票购买,Longeveron Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction